Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages.
Drummer C 4th, Saaoud F, Jhala NC, Cueto R, Sun Y, Xu K, Shao Y, Lu Y, Shen H, Yang L, Zhou Y, Yu J, Wu S, Snyder NW, Hu W, Zhuo J', Zhong Y, Jiang X, Wang H, Yang X.
Front Immunol. 2023 Jan 26;14:1113883. doi: 10.3389/fimmu.2023.1113883. eCollection 2023.
Signaling pathways in uric acid homeostasis and gout: From pathogenesis to therapeutic interventions.
Yang S, Liu H, Fang XM, Yan F, Zhang Y.
Int Immunopharmacol. 2024 May 10;132:111932. doi: 10.1016/j.intimp.2024.111932. Epub 2024 Apr 1.
The effect of hyperlipidemia on overall survival in patients with cancer was differentiated by BMI and hyperlipidemia type.
Tian HY, Yang M, Xie HL, Ruan GT, Ge YZ, Zhang XW, Zhang HY, Liu CA, Liu T, Shi HP.
Nutr Metab (Lond). 2024 Jun 24;21(1):37. doi: 10.1186/s12986-024-00811-1.
Drugs targeting peroxisome proliferator-activated receptors.
Xie Z, Xin J, Huang C, Liao C.
Drug Discov Today. 2025 Mar;30(3):104318. doi: 10.1016/j.drudis.2025.104318. Epub 2025 Feb 20.
Cyanotoxin exposure and hepatocellular carcinoma.
Hernandez BY, Zhu X, Nagata M, Loo L, Chan O, Wong LL.
Toxicology. 2023 Mar 15;487:153470. doi: 10.1016/j.tox.2023.153470. Epub 2023 Feb 28.
Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges.
Brandfon S, Eylon A, Khanna D, Parmar MS.
Cureus. 2023 Oct 7;15(10):e46623. doi: 10.7759/cureus.46623. eCollection 2023 Oct.
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.
Pohlman N, Patel PN, Essien UR, Tang JJ, Joseph JJ.
J Clin Endocrinol Metab. 2025 May 19:dgaf295. doi: 10.1210/clinem/dgaf295. Online ahead of print.
Periodontitis: a newly identified comorbidity in psoriasis and psoriatic arthritis.
Dalmády S, Kemény L, Antal M, Gyulai R.
Expert Rev Clin Immunol. 2020 Jan;16(1):101-108. doi: 10.1080/1744666X.2019.1700113. Epub 2019 Dec 11.
Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
Clin Ther. 2004 Oct;26(10):1599-607. doi: 10.1016/j.clinthera.2004.10.008.
Lipid-lowering effect of the new drugs eniclobrate and beclobrate in patients with hyperlipidemia type II a and type II b.
Najemnik C, Lageder H, Regal H, Irsigler K.
Arzneimittelforschung. 1981;31(12):2168-9.
